I took a small position this week and will look to build on it leading up to end of the patient component in the phase 1 trial.
One element that struck me watching the March Investor videos on their website is that they have a very aggressive strategy for partnering and expanding on indications. And yet, proving the efficacy of the first medication in the patient cohort, AD-214, is still some time away. It's a fearless risky strategy!
Is everyone expecting a relatively quiet rest of 2020 until the AD-214 healthy patient cohort data becomes available?
GLAH
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.142M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $5.858K | 2.928M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 25599399 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 6805828 | 16 |
View Market Depth
| Last trade - 16.15pm 24/06/2025 (20 minute delay) ? |
| 1AD (ASX) Chart |